Intervention not reported
Adverse events－serious events Budesonide/formoterol (BDF) versus budesonide (BD) · patients with COPD
It is very uncertain whether the intervention changes adverse events－serious events Budesonide/formoterol (BDF) versus… (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events－serious Mometasone/formoterol (MF/F) versus Mometasone (MF) · patients with COPD
The intervention showed no clear difference in adverse events－serious Mometasone/formoterol (MF/F) versus… (low certainty).
1 finding from 1 review
Annual Exacerbation Rates · COPD
Combined inhalers may leads to lower annual Exacerbation Rates compared with LABAs (low certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · COPD
Combined inhalers probably leads to lower number of people experiencing one or more exacerbations compared with LABAs (moderate certainty).
1 finding from 1 review
Annual hospitalisation rates · COPD
It is very uncertain whether combined inhalers changes annual hospitalisation rates compared with LABAs (very low certainty).
1 finding from 1 review
All‐cause mortality · COPD
Combined inhalers showed no clear difference in mortality compared with LABAs (moderate certainty).
1 finding from 1 review
Pneumonia · COPD
Combined inhalers probably leads to higher pneumonia compared with LABAs (moderate certainty).
1 finding from 1 review
Adherence · people taking self‐administered medications
2 findings from 1 review
Systolic blood pressure · people taking self‐administered medications
1 finding from 1 review
Diastolic blood pressure · people taking self‐administered medications
1 finding from 1 review
HbA1c (%) · people taking self‐administered medications
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days‐ short‐term treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction or stroke1
It is very uncertain whether the intervention changes all‐cause mortality at 2 days ‐ immediate treatment (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction or stroke1
It is very uncertain whether the intervention changes all‐cause mortality at 10 days ‐ short‐term treatment (very low certainty).
1 finding from 1 review